EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life

Lesley A Graff, Sharyle Fowler, Jennifer L Jones, Eric I Benchimol iD, Alain Bitton, James Guoxian Huang, M Ellen Kuenzig iD, Gilaad G Kaplan iD, Kate Lee, Mariam S Mukhtar, Parul Tandon iD, Laura E Targownik und 2 weitere

Journal of the Canadian Association of Gastroenterology · 05.11.2021 · 4 (Supplement_2) · S46-S53

DOI: 10.1093/jcag/gwab031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 05.11.2021. Verfasst von Lesley A Graff und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, …. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crohn's and Colitis Canada, Canadian Institutes of Health Research, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There has been a dramatic rise in mental health difficulties during the coronavirus disease 2019 (COVID-19) pandemic. While young adults have the lowest risk of hospitalization and mortality due to COVID-19, they have been identified as being at highest risk of detrimental mental health outcomes during the pandemic, along with women, those with lower socioeconomic status and those with pre-existing mental health conditions. Somewhat of a crisis in mental health has emerged across the general population through the evolution of the pandemic. A national Canadian survey identified a quadrupling of those experiencing pervasive elevated anxiety symptoms early in the pandemic compared to pre-pandemic levels, and a doubling of those with pervasive elevated depressive symptoms. Independent of the pandemic, persons with inflammatory bowel disease (IBD) can face multiple challenges related to their disease, which can result in a significant psychosocial burden and psychologic distress. Anxiety and depression have been found to be more prevalent in persons with IBD. Many potential factors contribute to the increased psychologic distress and negative impacts on mental health of the COVID-19 pandemic on persons with IBD. These include the fears of contracting COVID-19 or infecting other people. Many believe that IBD or its treatments predispose them to an increased risk of COVID-19 or a worse outcome if acquired. Concerns about access to health care add to mental distress. People with IBD generally report lower quality of life (QOL) compared to community controls. Psychologic interventions, in addition to adequate disease control, have been shown to improve health-related QOL. Uncertainty is another factor associated with reduced health-related QOL. Most studies suggest that persons with IBD have suffered QOL impairment during the pandemic in comparison to the pre-pandemic period. Uncertainties brought on by the pandemic are important contributors for some of the reduction in QOL.

Schlagwörter

Stichwörter der Autor:innen

CoronavirusCrohn’s diseaseMental healthQuality of lifeSARS-CoV-2Ulcerative colitis

Autor:innen und Institutionen

  • Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
  • Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.

ORCID-Profile: Eric I Benchimol, M Ellen Kuenzig, Gilaad G Kaplan, Parul Tandon, Joseph W Windsor, Charles N Bernstein

Förderung

  • Crohn's and Colitis Canada
  • Canadian Institutes of Health Research
  • Pfizer
  • AbbVie Corporation
  • Takeda Canada Inc.

Zitieren

APA

Graff, L. A., Fowler, S., Jones, J. L., Benchimol, E. I., Bitton, A., Huang, J. G., Kuenzig, M. E., Kaplan, G. G., Lee, K., Mukhtar, M. S., Tandon, P., Targownik, L. E., Windsor, J. W., & Bernstein, C. N. (2021). Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 4(Supplement_2), S46-S53. https://doi.org/10.1093/jcag/gwab031

Vancouver

Graff LA, Fowler S, Jones JL, Benchimol EI, Bitton A, Huang JG, et al. Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology. 2021;4(Supplement_2):S46-S53. doi:10.1093/jcag/gwab031

BibTeX
@article{Graff2021,
  author = {Graff, Lesley A and Fowler, Sharyle and Jones, Jennifer L and Benchimol, Eric I and Bitton, Alain and Huang, James Guoxian and Kuenzig, M Ellen and Kaplan, Gilaad G and Lee, Kate and Mukhtar, Mariam S and Tandon, Parul and Targownik, Laura E and Windsor, Joseph W and Bernstein, Charles N},
  title = {Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life},
  journal = {Journal of the Canadian Association of Gastroenterology},
  year = {2021},
  volume = {4},
  number = {Supplement_2},
  pages = {S46--S53},
  doi = {10.1093/jcag/gwab031}
}
Kostenlos starten →